The drug company Sanofi-Aventis, based in France told that important distinctions continued to stay, despite that it has extended its tender to the U. S. firm Genzyme not even having raise in its price.

The total tender that was extended to Genzyme, is offering its share at a rate of $69 per share. This is being regarded as a formality that will even put burden on Genzyme's board of directors to carry on the negotiations, as reported by the media on Monday.

The negotiations between the two nations are regarding an agreement upon a value for a multiple sclerosis drug known as Lemtrada which is being developed by Genzyme.

According to a statement made by Sanofi, there are still reminiscences of vital distinctions on Lemtrada's potential, and there is not any guarantee that both the parties will conclude an agreement.

However, the shareholders were able to find reason for making sale in case the stock value of Genzyme came down. Genzyme stock shut down at a rate of $71.58 per share last Friday over the Nasdaq exchange.

The board of directors of Genzyme has asked the shareholders to keep a grip over their shares. This weekend, Sanofi had bought a mere 3.29 million worth of shares.